Targeting Nrf2 in Protection Against Renal Disease

Related Experiment Video

Updated: Mar 2, 2026

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing
09:02

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing

Published on: June 9, 2017

24.6K

Melania Guerrero-Hue1, Victor Farre-Alins2, Alejandra Palomino-Antolin2

  • 1Renal, Vascular and Diabetes Research Laboratory, Instituto de Investigacion Sanitaria -Fundacion Jimenez Diaz, Autonoma University, 28040 Madrid. Spain.

Current Medicinal Chemistry
|May 13, 2017
PubMed
Abstract

Insights

Nuclear factor erythroid 2-related factor 2 (Nrf2) shows promise in protecting against kidney disease by reducing oxidative stress and inflammation. Further research is needed to confirm its safety and efficacy in human therapies.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Renal disease incidence and prevalence are increasing globally.
  • Oxidative stress and inflammation are key drivers in kidney disease pathogenesis and progression.
  • Targeting oxidative stress presents a potential therapeutic avenue for renal disease.

Purpose of the Study:

  • To review the protective mechanisms of nuclear factor erythroid 2-related factor 2 (Nrf2) in renal disease.
  • To describe novel Nrf2-targeting compounds and their effectiveness.
  • To summarize ongoing clinical trials for Nrf2-based therapies in renal conditions.

Main Methods:

  • A structured literature search of bibliographic databases was conducted.
  • Peer-reviewed research on Nrf2 activators and renal disease was analyzed.
  • Focus on studies detailing Nrf2's role in kidney pathophysiology.

Main Results:

  • Nrf2 regulates cellular resistance to oxidants and inflammation.
  • Nrf2 activation demonstrates protective effects against oxidative stress and inflammation in acute kidney injury and chronic kidney disease.
  • Low-dose Nrf2 activation shows renoprotective benefits, while higher doses may be harmful; limited human clinical trials exist.

Conclusions:

  • Nrf2 activation shows potential for mitigating renal disease progression.
  • Further clinical studies are essential to validate the safety and efficacy of Nrf2-targeting therapies in humans.
  • The dose-dependent effects of Nrf2 activators require careful consideration for therapeutic application.
Keywords:
Nrf2acute and chronic kidney injuryinflammationoxidationrenal damagetherapy

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1000

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
397
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.3K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
537
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.1K